Abstracts tagged "Myositis"

Abstract Number: 1166 • ACR Convergence 2024
Characteristics, Treatments, and Outcomes of Patients with Dermatomyositis from Two Large, Nationwide US Cohorts
Michael George¹, Thomas Riley², Ellen Romich³, Bryant England⁴, Jessica Chung⁵, Karim Masri⁶, Shanette Daigle⁷, Emily Holladay⁸, Yujie Su⁹, Fenglong xie¹⁰ and Jeffrey Curtis¹¹, ¹University of Pennsylvania, Philadelphia, PA, ²Hopsital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Media, PA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Pfizer, New York, NY, ⁶Pfizer Inc, Collegeville, PA, ⁷FASTER, Birmingham, AL, ⁸University of Alabama at Birmingham, Edmond, OK, ⁹Illumination Health, Hoover, AL, ¹⁰University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ¹¹Illumination Health, Birmingham, AL
Background/Purpose: Studies of dermatomyositis (DM) are frequently limited to single center cohorts at academic centers. We aimed to use two large nationally representative US cohorts…
Abstract Number: 1750 • ACR Convergence 2024
Safety and Preliminary Efficacy of CD19 CAR-T Cell Treatment in Rheumatic Disease – Data from the First Part of the Phase I/II CASTLE Basket Study
Georg Schett¹, Fabian Müller², Melanie Hagen³, Andreas Wirsching³, Daniela Bohr⁴, Christina Bergmann⁵, Carlo Tur³, Simon Völkl⁶, Michael Aigner⁷, Sascha Kretschmann⁷, Silvia Spoerl⁷, Soraya Kharboutli⁷, Ingrid Vasova⁷, Daniel Aletaha⁸, Hans Kiener⁹, Gerlando Natalello¹⁰, Franco Locatelli¹¹, Maria Antonietta D´Agostino¹², Aline Bozec³, Ricardo Grieshaber-Bouyer¹³ and Andreas MAckensen¹⁴, ¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ²Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ³Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, ⁶Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ⁷Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ⁹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ¹⁰Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ¹¹IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ¹²Catholic University of Sacred Heart, Rome, Italy, Rome, Italy, ¹³Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ¹⁴Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany
Background/Purpose: Systemic autoimmune diseases are based on an aberrant activation of B cells. Autologous CD19 chimeric antigen receptor (CAR) T cells allow deep depletion of…
Abstract Number: 2079 • ACR Convergence 2024
Understanding Relapse Patterns in Anti-HMGCR Statin-induced IMNM: A Detailed Comparative Study
Silvia Grazzini¹, Angeles Galindo-Feria², Edoardo Conticini¹, Ingrid Lundberg³ and Maryam Dastmalchi⁴, ¹Università di Siena, Siena, Italy, ²Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska University hospital, Stockholm, Sweden
Background/Purpose: Statin-induced immune-mediated necrotizing myopathy (IMNM) is a recently recognized subtype of idiopathic inflammatory myopathy (IIM). This condition is marked by the sudden onset of…
Abstract Number: 2670 • ACR Convergence 2024
Sera from Patients with Idiopathic Inflammatory Myopathy Induces Muscle Weakness, Mitochondrial Dysfunction and Induction of Cytokines in Isolated Skeletal Muscle
Cecilia Leijding¹, Suchada Kaewin², Kristofer Andreasson¹, Tomas Schiffer¹, Angeles Galindo-Feria³, Begum Horuluoglu¹, Mattias Carlstrom¹, Stefano Gastaldello¹, Helene Alexanderson⁴, Ingrid Lundberg⁵ and Daniel Andersson⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, ³Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁶Karolinska Institutet, Solna, Sweden
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of systemic autoimmune inflammatory muscle disorders characterized by symmetrical skeletal muscle weakness and accelerated fatigue. Although signs…
Abstract Number: 0163 • ACR Convergence 2024
Modification of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis, Clinically Amyopathic Dermatomyositis, and Immune-mediated Necrotizing Myopathy
Ching Chung¹, Yusra Hasan², Rajesh Gopalarathinam³, shiri keret⁴, Dana Ascherman⁵, Siamak Mogahadam⁶, Chester Oddis⁶ and Rohit Aggarwal⁷, ¹UPMC McKeesport, Pittsburgh, PA, ²CHI health Creighton university medical center, Omaha, NE, ³Division of Rheumatology, Wrightington Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan, United Kingdom, ⁴Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: The 2017 ACR/EULAR classification criteria for idiopathic inflammatory myopathies (IIM) currently used in myositis clinical trials/research demonstrated 87% sensitivity and 82% specificity for a…
Abstract Number: 0342 • ACR Convergence 2024
Measurement of Serum Cytokine and Chemokine Level to Predict Poor Treatment Response in Patients with Idiopathic Inflammatory Myositis
Sung Ik Cho¹, Miriam Kim², Ju yeon Kim³, Jin Kyun Park⁴, Eun Young Lee⁵, eun Bong Lee⁶ and Jun Won park³, ¹Seoul National University Hospital, Jongno-gu, Seoul-t'ukpyolsi, Republic of Korea, ²Seoul National University, Seoul, Republic of Korea, ³Seoul National University Hospital, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁴Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, ⁵3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ⁶Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: To investigate whether serum levels of cytokine and chemokine can predict a treatment response in patients with idiopathic inflammatory myositis (IIM)Methods: This study included…
Abstract Number: 1147 • ACR Convergence 2024
Evaluation of Adverse Pregnancy Outcomes in Patients with Inflammatory Myopathies and Ro Positivity
Hillary Weisleder¹, Ana Valle², Caroline Rourke³ and Shereen Mahmood⁴, ¹Montefiore Einstein, New York, NY, ²Brigham and Women's Hospital, Boston, MA, ³Montefiore Medical Center, Bronx, NY, ⁴Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Anti-Ro/SSA antibodies are associated with poor prognostic outcomes in patients with autoimmune disease. The presence of these antibodies can also cause adverse pregnancy outcomes…
Abstract Number: 1167 • ACR Convergence 2024
Construction of a Refractory Myositis Predictive Index (ReMPI) in a Cohort of Patients with Idiopathic Inflammatory Myopathies
Andres Gaytan Garcia de Alba¹, Nancy R Mejía-Domínguez¹, Yatzil Reyna-Juárez¹, Beatriz Alcalá-Carmona¹, María José Ostos-prado¹, Agustin Hernandez Lopez¹, Diana Gomez-martin² and Jiram Torres Ruiz³, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ²INCMNSZ, Mexico City, Federal District, Mexico, ³INCMNSZ, Mexico, Federal District, Mexico
Background/Purpose: An important proportion of patients with Idiopathic inflammatory myopathies (IIM) are at risk of developing refractory disease, which predispose them to cumulate damage, treatment…
Abstract Number: 1763 • ACR Convergence 2024
Circulating NK and CD8+ Cytotoxic T Cells in Treatment Naïve JDM Demonstrate Higher Cytotoxic and Interferon Signature as Compared to Childhood-Onset SLE
Qinmengge Li¹, Celine Berthier¹, Christine Goudsmit¹, Sophia Matossian¹, Rachael Wasikowski², Johann Gudjonsson¹, J. Michelle Kahlenberg¹, Lam C. Tsoi² and Jessica Turnier³, ¹University of Michigan, Ann Arbor, MI, ²Michigan, Dept. of Dermatology, Ann Arbor, MI, ³University of Michigan, Saline, MI
Background/Purpose: Juvenile dermatomyositis (JDM) and childhood-onset systemic lupus erythematosus (cSLE) are pediatric autoimmune diseases that can present with overlapping clinical features yet have unique tropism…
Abstract Number: 2080 • ACR Convergence 2024
HLA-DRB1*11:01 Association Differenciates Anti-hmgcr Immune-mediated Necrotizing Myopathy from Non-immune Mediated Statin Myotoxicity
Cristina Corrales Selaya¹, Diana Prieto-Peña², gonzalo Ocejo-Viñals³, Carmen Secada Gómez⁴, alfonso Corrales-Martínez⁵, Carmen Ibarbia⁶, Zaida Salmón-gonzalez⁶, Marta Martín-millan⁶, Virginia Portilla-González⁶, Nerea mota-perez⁶, M. sebastian-mora gil⁶, J.C Batista-liz⁶, Veronica Pulito-Cueto⁷, Raquel Lopez-mejias⁷, Ricardo Blanco-Alonso⁸ and Jose Luis Hernandez⁶, ¹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁶Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁷IDIVAL, Santander, Spain, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Genetic risk factors may explain why only a small proportion of patients taking statins develop severe cases of anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) immune-mediated necrotizing myopathy…
Abstract Number: 0319 • ACR Convergence 2024
Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis
Farbod Moghaddam¹, Mark Tarnopolsky², Valérie Leclair³, marie Hudson³, Ross Mitchell⁴, Katherine Buhler¹, Erin Hatcher⁵, Meifeng Zhang¹, Antoine Dufour¹, Luiz de Almeida¹, Marvin Fritzler⁶ and May Choi¹, ¹University of Calgary, Calgary, AB, Canada, ²McMaster University, Hamilton, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, Canada, ⁵McMaster University, Hamilton, Canada, ⁶Mitogen Diagnostics Corp, Calgary, AB, Canada
Background/Purpose: Sporadic inclusion body myositis (sIBM) is often challenging to diagnose because many patients have no known biomarkers (seronegative). Machine learning was applied to identify…
Abstract Number: 0343 • ACR Convergence 2024
An Interlaboratory Variability Study of Detection Methods for Myositis-Specific and Myositis-Associated Autoantibodies in Sera from Patients with Idiopathic Inflammatory Myopathies
Georgina Harvey¹, Idil Ashur², Xavier Bossuyt³, Martin Bluethner⁴, Anna Brusch⁵, Chris Bundell⁵, hector Chinoy⁶, Claire Coeshott⁷, Charmaine Donald², Juliet Dunphy⁸, Marvin Fritzler⁹, Adrian Heaps², marie Hudson¹⁰, Masataka Kuwana¹¹, Océane Landon-Cardinal¹², Hui Lu¹, FIONNUALA MCMORROW¹, Marie Mayrhofer⁴, Alain Meyer¹³, Birthe Michiels³, Benoit Nespola¹⁴, Susan O'Loughlin¹⁵, Ivana Putova¹⁶, Johan Rönnelid¹⁷, Ross Sadler¹⁸, Maria Teresa Sanz-Martinez¹⁹, Paul Sciore²⁰, Albert Selva-O’Callaghan²¹, Helena Storfors²², Ernesto Trallero-Araguás²³, Yves Troyanov¹², Jade Tyson², Jiří Vencovský²⁴, Akira Yoshida²⁵ and Sarah Tansley¹, ¹University of Bath, Bath, United Kingdom, ²Severn Pathology, North Bristol NHS Trust, Bristol, United Kingdom, ³University Hospitals Leuven, Leuven, Belgium, ⁴MVZ Labor PD Dr. Volkmann und Kollegen GbR, Karlsruhe, Germany, ⁵Department of Clinical Immunology, PathWest Laboratory Medicine, Perth, Western Australia, Australia, ⁶The University of Manchester, Manchester, United Kingdom, ⁷Advanced Diagnostics Laboratories National Jewish Health, Denver, CO, ⁸Royal United Hospital Bath NHS Foundation Trust, Bath, United Kingdom, ⁹Mitogen Diagnostics Corp, Calgary, AB, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹²Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ¹³UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ¹⁴Laboratoire d’immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹⁵Greater Manchester Immunology Service, Manchester, England, United Kingdom, ¹⁶Institute of Rheumatology, Prague, Czech Republic, ¹⁷Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ¹⁸Laboratory of Immunology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, England, United Kingdom, ¹⁹Immunology Division, Vall d'Hebron Hospital, Barcelona, Spain, ²⁰Mitogen Diagnostics Corp., Calgary, ²¹Internal Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain, ²²Department of Clinical Immunology and Transfusion Medicine, Uppsala University Hospital, Uppsala, Sweden, ²³Rheumatology Departament, Vall d'Hebron Hospital, Barcelona, Spain, ²⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²⁵Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
Background/Purpose: In idiopathic inflammatory myopathy (IIM) spectrum diseases, myositis-specific and myositis-associated autoantibodies (MSAs/MAAs) are key markers of disease subtype and prognosis and are considered routine…
Abstract Number: 1149 • ACR Convergence 2024
Cause-Specific Proportionate Mortality Trends in Idiopathic Inflammatory Myopathies
Ansaam Daoud¹, Muhammad Shamim², Loai Dweik³ and Haseeb Chaudhary⁴, ¹Case Western Reserve University/University Hospitals, Akron, OH, ²University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ³Cleveland Clinic Akron General Internal Medicine, Akron, OH, ⁴Case Western Reserve University, Westlake, OH
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are associated with increased morbidity, mortality, and economic health burden compared to the general population despite advancements in overall disease management.…
Abstract Number: 1168 • ACR Convergence 2024
Improved Survival in Patients with Myositis-Associated Interstitial Lung Disease (ILD) During the Period 2011 to 2023: Comparative and Integrative Analysis of Three Multicenter Cohorts in Japan
Masataka Kuwana¹, Kenichi Masui², Atsushi Kawakami³, Takafumi Suda⁴, Shinji Sato⁵, Yasushi Kawaguchi⁶, Takeshi Johkoh⁷, Tomoaki Hoshino⁸, Naoki Shimada⁹, Yasuhiro Kondoh¹⁰, Yoshinori Tanino¹¹, Tohru Takeuchi¹², Yoshiyuki Abe¹³, Naoki Kimura¹⁴, Yasushi Inoue¹⁵, Keisuke Tomii¹⁶, Toru Arai¹⁷, Kunihiro Yamaoka¹⁸, Kaneshige Sasaki¹⁹, Taio Naniwa²⁰, Ran Nakashima²¹, Kenjiro Shima²², Osamu Nishiyama²³, Yuko Waseda²⁴, Hiroshi Mukae²⁵, Hirofumi Chiba²⁶, Keigo Ikeda²⁷, Kazuya Ichikado²⁸, Yohei Kirino², Koichi Amano²⁹, Takashi Nawata³⁰, Tomoo Kishaba³¹, Daisuke Asatori³², Daisuke Kobayashi²² and Takahisa Gono³³, ¹Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ²Yokohama City University School of Medicine, Yokohama, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁵Tokai University School of Medicine, Isehara, Japan, ⁶Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁷Kansai Rosai Hospital, Amagasaki, Japan, ⁸Kurume University School of Medicine, Kurume, Japan, ⁹International University of Health and Welfare, Ohtawara, Japan, ¹⁰Tosei General Hospital, Seto, Japan, ¹¹Fukushima Medical University School of Medicine, Fukushima, Japan, ¹²Osaka Medical and Pharmaceutical University, Takatsuki, Japan, ¹³Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan, ¹⁶Kobe City Medical Center General Hospital, Kobe, Japan, ¹⁷NHO Kinki Chuo Chest Medical Center, Sakai, Japan, ¹⁸Kitasato University School of Medicine, Sagamihara, Japan, ¹⁹Kainan Hospital, Yatomi, Japan, ²⁰Nagoya City University, Nagoya, Japan, ²¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²²Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²³Kindai University Faculty of Medicine, Osakasayama, Japan, ²⁴University of Fukui, Eiheiji, Japan, ²⁵Nagasaki University Hospital, Nagasaki, Japan, ²⁶Sapporo Medical University, Sapporo, Japan, ²⁷Juntendo University Urayasu Hospital, Urayasu, Japan, ²⁸Saiseikai Kumamoto Hospital, Kumamoto, Japan, ²⁹Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan, ³⁰Yamaguchi University Graduate School of Medicine, Ube, Japan, ³¹Okinawa Chubu Hospital, Uruma, Japan, ³²Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, ³³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: ILD is the leading cause of mortality in patients with idiopathic inflammatory myopathies, and rapidly progressive ILD, associated mainly with anti-MDA5 antibody, is the…
Abstract Number: 1779 • ACR Convergence 2024
Single-Nuclear RNA-Sequencing of Treatment Naïve JDM Muscle Highlights Dysregulated Vascular Integrity and Angiogenesis in Endothelial Cells and Decreased Nitric Oxide Synthase Signaling in Type II Muscle Fibers
Jessica Turnier¹, Chioma Madubata², Christine Goudsmit³, Sean Ferris³, Celine Berthier³, Zilan Zheng⁴, Sophia Matossian³, Jeff Dvergsten⁵, Meredyth Wilkinson⁶, Lucy R Wedderburn⁷, Gabrielle Morgan⁸, Lauren Pachman⁹, Claudia Lalancette³, Stephen Parker³, Andrew Heaton¹⁰, J. Michelle Kahlenberg³, Gabriela K Fragiadakis² and Jessica Neely⁴, ¹University of Michigan, Saline, MI, ²University of California, San Francisco, San Francisco, CA, ³University of Michigan, Ann Arbor, MI, ⁴UCSF, San Francisco, CA, ⁵Duke University Hospital, Hillsborough, NC, ⁶Great Ormond Street Institute of Child Health, London, United Kingdom, ⁷UCL GOS Institute of Child Health, London, United Kingdom, ⁸Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹⁰Cure JM, Leesburg, VA
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children, and it frequently follows a chronic disease course. Treatments are limited secondary…

« Previous Page
1
…
3
4
5
6
7
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].